Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Litigation
Patents
PipCast®
PTE
Webinars

Amgen to buy ChemoCentryx for nearly $4 billion

Aug 4, 2022

Amgen announced that it has agreed to acquire ChemoCentryx, a biopharmaceutical company focused on auto-immune diseases, inflammatory disorders and cancer, for around $3.7 billion.  ChemoCentryx markets Tavneos® (avacopan), a first-in-class treatment for multi-system autoimmune diseases involving small vessel inflammation.

Print Page Mail Article